Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCURAY INCARAY · Entity 1170 | Director | November 30, 2017 | December 04, 2017 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | August 17, 2018 | August 21, 2018 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 14, 2017 | June 16, 2017 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | March 09, 2012 | March 12, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCURAY INC
Report date November 30, 2017 · Filed December 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,181 |
Reported balance
After 2017-11-30 transaction · row 1
1 source rowRow 1 · 2017-11-30 · Grant · Acquired 29,126 · Balance 162,181 F1: All of the restricted stock units vest one year from the vesting commencement date. F2: This grant is represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of ARAY common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock units vest one year from the vesting commencement date.
F2: This grant is represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of ARAY common stock.
NEKTAR THERAPEUTICS
Report date August 17, 2018 · Filed August 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,750 |
Last balance in matching sequence
After 2018-08-21 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2018-08-17 · Exercise / conversion · Acquired 15,000 · Balance 57,750 F1: This transaction was made for stock options scheduled to expire on September 14, 2018. Row 2 · 2018-08-17 · Sale · Disposed 15,000 · Balance 42,750 F1: This transaction was made for stock options scheduled to expire on September 14, 2018. F2: This transaction was executed in multiple trades at prices ranging from $59.61 to $59.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Row 3 · 2018-08-21 · Exercise / conversion · Acquired 15,000 · Balance 57,750 F1: This transaction was made for stock options scheduled to expire on September 14, 2018. Row 4 · 2018-08-21 · Sale · Disposed 15,000 · Balance 42,750 F1: This transaction was made for stock options scheduled to expire on September 14, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.26 · Expires 2018-09-14 | Direct | 15,000 |
Reported balance
After 2018-08-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-08-17 · Exercise / conversion · Disposed 15,000 · Balance 15,000 F1: This transaction was made for stock options scheduled to expire on September 14, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.26 · Expires 2018-09-14 | Direct | 0 |
Reported balance
After 2018-08-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-08-21 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: This transaction was made for stock options scheduled to expire on September 14, 2018. |
| Common StockSEC Table I · non-derivative | Indirectby Family Trust | 5,000 |
Reported balance
Holding disclosure · report date 2018-08-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made for stock options scheduled to expire on September 14, 2018.
F2: This transaction was executed in multiple trades at prices ranging from $59.61 to $59.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Pacira BioSciences, Inc.
Report date June 14, 2017 · Filed June 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,490 |
Reported balance
After 2017-06-14 transaction · row 1
1 source rowRow 1 · 2017-06-14 · Grant · Acquired 1,357 · Balance 7,490 F1: Represents restricted stock units that vest on June 3, 2018, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.20 · Expires 2027-06-14 | Direct | 2,714 |
Reported balance
After 2017-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-14 · Grant · Acquired 2,714 · Balance 2,714 F2: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 3, 2018, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date March 09, 2012 · Filed March 12, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,500 |
Ending reported balance
After 2012-03-09 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2012-03-09 · Grant · Acquired 18,750 · Balance 25,250 Row 2 · 2012-03-09 · Grant · Acquired 20,000 · Balance 45,250 Row 3 · 2012-03-09 · Disposition to issuer · Disposed 38,750 · Balance 6,500 F1: Open market sales reported on this line occurred at a weighted average price of $41.65 (range $41.61 to $41.74). F2: Mr. Winger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.05 · Expires 2019-07-05 | Direct | 11,250 |
Reported balance
After 2012-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2012-03-09 · Exercise / conversion · Disposed 18,750 · Balance 11,250 F3: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments over four years. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.24 · Expires 2020-05-31 | Direct | 0 |
Reported balance
After 2012-03-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2012-03-09 · Exercise / conversion · Disposed 20,000 · Balance 0 F4: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market sales reported on this line occurred at a weighted average price of $41.65 (range $41.61 to $41.74).
F2: Mr. Winger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments over four years.
F4: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2018 Filed Aug 21, 2018 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 15,000 | $14.26 Strike: $14.26 | $213,900.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · derivative · entry 7 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 21, 2018 Filed Aug 21, 2018 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 15,000 | $60.30 | $904,500.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · nonDerivative · entry 4 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,750 F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 21, 2018 Filed Aug 21, 2018 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $14.26 | $213,900.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · nonDerivative · entry 3 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 15,000 | $14.26 Strike: $14.26 | $213,900.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · derivative · entry 6 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2018-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 15,000 | $59.62 | $894,300.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · nonDerivative · entry 2 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,750 F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $59.61 to $59.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $14.26 | $213,900.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 17,125 | $60.15 | $1,030,068.75 |
DisclosureSEC source: 0001209191-18-046899 · doc4.xml · nonDerivative · entry 2 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,750 F2 · price: This transaction was executed in multiple trades at prices ranging from $60.09 to $60.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 17,125 | $61.04 | $1,045,310.00 |
DisclosureSEC source: 0001209191-18-046899 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,875 F1 · price: This transaction was executed in multiple trades at prices ranging from $61.03 to $61.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 11,250 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001209191-18-002773 · doc4.xml · derivative · entry 4 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2018-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on January 15, 2018. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 22,500 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001209191-18-002773 · doc4.xml · derivative · entry 3 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2018-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on January 15, 2018. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 33,750 | $11.97 | $403,987.50 |
DisclosureSEC source: 0001209191-18-002773 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on January 15, 2018. Read SEC document |
| November 30, 2017 Filed Dec 4, 2017 22:21 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 29,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001138723-17-000078 · edgardoc.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,181 F1 · kind: All of the restricted stock units vest one year from the vesting commencement date. F2 · shares: This grant is represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of ARAY common stock. Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 23:19 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 9,505 | $4.80 | $45,624.00 |
DisclosureSEC source: 0001138723-17-000054 · edgardoc.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,055 F1 · shares: These shares were forfeited due to a cash settlement election made by the director in the grant agreement. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:57 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-17-053625 · doc4.xml · derivative · entry 3 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: common stock · 22,500 shares Expires 2025-09-18 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:57 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053625 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 19, 2017. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 2,714 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040694 · doc4.xml · derivative · entry 2 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,714 Underlying: Common Stock · 2,714 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040694 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,490 F1 · shares: Represents restricted stock units that vest on June 3, 2018, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| November 30, 2016 Filed Dec 3, 2016 00:27 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 23,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001138723-16-000156 · edgardoc.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,560 F1 · kind: All of the restricted stock units vest one year from the vesting commencement date. F2 · shares: This grant is represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of ARAY common stock. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 23:45 UTC | ACCURAY INC ARAY · Entity 1170 | Tax withholdingCommon Stock | 6,818 | $5.30 | $36,135.40 |
DisclosureSEC source: 0001138723-16-000136 · edgardoc.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,798 F1 · shares: These shares were forfeited due to a cash settlement election made by the director in the grant agreement. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001209191-16-142670 · doc4.xml · derivative · entry 3 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-09-20 F3 · derivative.exercise_date: This option vests in equal monthly installments over the one-year period beginning on September 30, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142670 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,250 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 21, 2016. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:17 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142031 · doc4.xml · derivative · entry 3 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F1 · derivative.exercise_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F1 · derivative.expiration_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:17 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142031 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F2 · balance_after: The total holdings includes the 15,000 shares of restricted stock units ("RSUs") that were previously reported in Table II for the reporting person and which are being reclassified to Table I. These RSUs were granted on September 15, 2015, are convertible on a one-for-one basis into shares of Common Stock of the Company, and vested on September 15, 2016. Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · derivative · entry 5 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 18,750 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · derivative · entry 4 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 18,750 shares Expires 2019-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments over four years. Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 38,750 | $41.65 | $1,613,937.50 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · nonDerivative · entry 3 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · price: Open market sales reported on this line occurred at a weighted average price of $41.65 (range $41.61 to $41.74). F2 · price: Mr. Winger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,000 | $34.24 | $684,800.00 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · nonDerivative · entry 2 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,250 Read SEC document |
| March 09, 2012 Filed Mar 12, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 18,750 | $34.05 | $638,437.50 |
DisclosureSEC source: 0001209191-12-017501 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,250 Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-11-032549 · doc4.xml · derivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2021-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000032 · edgar.xml · derivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 18:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 6,500 | $38.54 | $250,510.00 |
DisclosureSEC source: 0000875320-10-000013 · edgar.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Self as Trustee for the Dennis L. Winger and Barbara L. Waldman Rev. Trust Disclosed balance after: 6,500 Read SEC document |
| July 06, 2009 Filed Jul 7, 2009 20:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0000875320-09-000057 · edgar.xml · derivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2019-07-05 F1 · shares: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.